Better Therapeutics Inc (BTTX) Actualités

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases...

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

Savings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes Better Therapeutics, Inc...

Form 8-K - Current report

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Better Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way...